| # | Drug | Count |
|---|---|---|
| 0 | LEUPROLIDE ACETATE | 1131 |
| 1 | TOCILIZUMAB | 333 |
| 2 | ALTEPLASE | 244 |
| 3 | OMALIZUMAB | 179 |
| 4 | RITUXIMAB | 163 |
| 5 | BEVACIZUMAB | 142 |
| 6 | DORNASE ALFA | 125 |
| 7 | PERTUZUMAB | 118 |
| 8 | TRASTUZUMAB | 117 |
| 9 | DENOSUMAB | 75 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DESONIDE OINTMENT, 0.05% | 1 | 0.5000 |
| 1 | RUBIDIUM CHLORIDE RB-82 | 2 | 0.0172 |
| 2 | ALTEPLASE | 244 | 0.0162 |
| 3 | AMLODIPINE AND VALSARTAN | 3 | 0.0152 |
| 4 | LEUPROLIDE ACETATE | 1131 | 0.0145 |
| 5 | CALCIPOTRIENE CREAM, 0.005% | 1 | 0.0097 |
| 6 | 3% SODIUM CHLORIDE | 1 | 0.0088 |
| 7 | NINTEDANIB ESYLATE | 3 | 0.0086 |
| 8 | METHOHEXITAL SODIUM | 1 | 0.0079 |
| 9 | TRASTUZUMAB-ANNS | 12 | 0.0079 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-6 Receptor Antagonist [EPC] | 333 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 221 |
| 2 | HER2/neu Receptor Antagonist [EPC] | 209 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 201 |
| 4 | Anti-IgE [EPC] | 179 |
| 5 | Recombinant Human Deoxyribonuclease 1 [EPC] | 125 |
| 6 | Corticosteroid [EPC] | 94 |
| 7 | Osmotic Laxative [EPC] | 80 |
| 8 | RANK Ligand Inhibitor [EPC] | 75 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 68 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Recombinant Human Deoxyribonuclease 1 [EPC] | 125 | 0.0064 |
| 1 | HER2/neu Receptor Antagonist [EPC] | 209 | 0.0028 |
| 2 | Interleukin-6 Receptor Antagonist [EPC] | 333 | 0.0024 |
| 3 | CD30-directed Immunoconjugate [EPC] | 24 | 0.0023 |
| 4 | Anti-IgE [EPC] | 179 | 0.0021 |
| 5 | CD4-directed Blocking Antibody [EPC] | 1 | 0.0019 |
| 6 | Selective T Cell Costimulation Blocker [EPC] | 7 | 0.0015 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 221 | 0.0012 |
| 8 | Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC] | 2 | 0.0011 |
| 9 | Adrenocorticotropic Hormone [EPC] | 1 | 0.0011 |